Privium Fund Management B.V. Takes Position in Stoke Therapeutics, Inc. $STOK

Key Points

• Privium Fund Management B.V. bought a new 55,000‑share stake in Stoke Therapeutics (NASDAQ:STOK) in Q4, valued at about $1.746 million and representing roughly 0.10% ownership.
• Research coverage has turned largely positive—Guggenheim initiated with a Buy and $60 target, several firms raised price objectives, and the consensus rating is "Moderate Buy" with an average price target of $41.83.
• Company insiders have been net sellers recently: Director Adrian Krainer sold 33,243 shares (~$1.32M) and insiders sold 69,699 shares (~$2.53M) in the past 90 days, leaving insiders with about 9.5% ownership.

Privium Fund Management B.V. bought a new stake in Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 55,000 shares of the company's stock, valued at approximately $1,746,000. Privium Fund Management B.V. owned 0.10% of Stoke Therapeutics at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Hussman Strategic Advisors Inc. purchased a new position in shares of Stoke Therapeutics in the fourth quarter valued at $2,000,000. Strs Ohio boosted its stake in shares of Stoke Therapeutics by 9.4% in the fourth quarter. Strs Ohio now owns 7,000 shares of the company's stock valued at $222,000 after purchasing an additional 600 shares during the period. Generali Investments Management Co LLC boosted its stake in Stoke Therapeutics by 41.0% during the 4th quarter. Generali Investments Management Co LLC now owns 2,471 shares of the company's stock valued at $78,000 after acquiring an additional 718 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in Stoke Therapeutics by 34.4% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 12,907 shares of the company's stock valued at $410,000 after acquiring an additional 3,302 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. boosted its stake in Stoke Therapeutics by 31.1% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,776 shares of the company's stock valued at $88,000 after acquiring an additional 658 shares during the last quarter.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the stock. Guggenheim assumed coverage on shares of Stoke Therapeutics in a research note on Thursday, February 5th. They set a "buy" rating and a $60.00 price objective on the stock. Wedbush increased their price objective on shares of Stoke Therapeutics from $36.00 to $38.00 and gave the company an "outperform" rating in a research note on Tuesday, March 17th. Needham & Company LLC increased their price objective on shares of Stoke Therapeutics from $35.00 to $40.00 and gave the company a "buy" rating in a research note on Tuesday, March 17th. Weiss Ratings reiterated a "hold (c)" rating on shares of Stoke Therapeutics in a research note on Friday, April 10th. Finally, Chardan Capital reiterated a "buy" rating and set a $35.00 price objective on shares of Stoke Therapeutics in a research note on Wednesday, March 18th. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and two have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $41.83.

Insider Activity at Stoke Therapeutics

In other Stoke Therapeutics news, Director Adrian R. Krainer sold 33,243 shares of the stock in a transaction on Tuesday, March 10th. The shares were sold at an average price of $39.74, for a total transaction of $1,321,076.82. Following the sale, the director directly owned 283,302 shares of the company's stock, valued at approximately $11,258,421.48. This represents a 10.50% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Barry Ticho sold 1,461 shares of the stock in a transaction on Thursday, March 19th. The stock was sold at an average price of $29.99, for a total transaction of $43,815.39. Following the sale, the insider directly owned 40,702 shares in the company, valued at $1,220,652.98. This trade represents a 3.47% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 69,699 shares of company stock valued at $2,526,714 in the last ninety days. 9.50% of the stock is owned by insiders.

Stoke Therapeutics Price Performance

NASDAQ STOK opened at $32.96 on Wednesday. Stoke Therapeutics, Inc. has a 12 month low of $8.30 and a 12 month high of $40.22. The company has a market capitalization of $2.05 billion, a price-to-earnings ratio of -274.64 and a beta of 1.20. The company's fifty day moving average price is $34.46 and its two-hundred day moving average price is $32.04.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last issued its earnings results on Monday, March 16th. The company reported ($0.97) earnings per share for the quarter. The business had revenue of $1.40 million for the quarter. Stoke Therapeutics had a negative return on equity of 2.05% and a negative net margin of 3.73%. As a group, analysts anticipate that Stoke Therapeutics, Inc. will post -3.41 EPS for the current year.

About Stoke Therapeutics

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company's lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.